IL6 and neoplasm: Under these conditions, as shown inFig. 8B, inhibition of factor Xa by EDX administration to mice suppresses PAR2 activation, reducing PAR2 levels, followed by a downregulation of the PAR2-mediated STAT3/IL-6 signaling pathway and the RAS/PI3K/SyK/Ki67/cyclin D1 signaling pathways (white downward arrows), resulting in tumor growth suppression.